1. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
   Hongwen Li et al, 2016, Cancer Biol Ther CrossRef
2. Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients
   Sumi Yun et al, 2017, Gastric Cancer CrossRef
3. Changing strategies for target therapy in gastric cancer
   Suk-young Lee, 2016, WJG CrossRef
4. null
   Shouji Shimoyama, 2017 CrossRef
5. Molecular classifications of gastric cancers: Novel insights and possible future applications
   Silvio Ken Garattini et al, 2017, WJGO CrossRef
6. Inhibition of Hes1 enhances lapatinib sensitivity in gastric cancer sphere-forming cells
   Luchun Li et al, 2017 CrossRef
7. miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer
   Xinliang Zhou et al, 2018, Cancer Gene Ther CrossRef
8. HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer
   Tetsushi Kubota et al, 2018, Nanomedicine: Nanotechnology, Biology and Medicine CrossRef
9. Biomarkers of gastric cancer: Current topics and future perspective
   Tasuku Matsuoka et al, 2018, WJG CrossRef
10. Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies
    Alessandra Raimondi et al, 2018, Pharmacogenomics CrossRef
11. What’s New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives
    Giuseppe Tirino et al, 2018, IJMS CrossRef
12. Gastric cancer: Basic aspects
    Henrique O. Duarte et al, 2018, Helicobacter CrossRef
13. The role of HER3 in gastric cancer
    Liying Wang et al, 2014, Biomedicine & Pharmacotherapy CrossRef
14. Recent advances in the HER2 targeted therapy of gastric cancer
    Tasuku Matsuoka, 2015, WJCC CrossRef
15. Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case
    Takuya Saito et al, 2015, Pathol Int CrossRef
16. null
    Milos Dokmanovic et al, 2015 CrossRef
17. A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells
    Chongchong Tian et al, 2015, Apoptosis CrossRef
18. Correlation between apparent diffusion coefficients and HER2 status in gastric cancers: pilot study
    Jian He et al, 2015, BMC Cancer CrossRef
19. Targeting HER 2 and angiogenesis in gastric cancer
    G Jomrich et al, 2016, Expert Review of Anticancer Therapy CrossRef
20. Targeted therapy in gastric cancer
    G. Jomrich et al, 2016, Eur Surg CrossRef
21. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer
    Hiromi Kataoka et al, 2016, Cancer Chemother Pharmacol CrossRef
22. PRL3-zumab, a first-in-class humanized antibody for cancer therapy
    Min Thura et al, 2016 CrossRef
23. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines
    Julia Kneissl et al, 2017, J Cancer Res Clin Oncol CrossRef
24. null
    Giuseppe Tridente, 2017 CrossRef
25. Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer
    Chiara Arienti et al, 2019, Front. Oncol. CrossRef
26. Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer
    Chiara Arienti et al, 2016, Oncotarget CrossRef
27. ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
    Eva A. Ebbing et al, 2016, Oncotarget CrossRef
28. null
    Dhananjay Shukla et al, 2020 CrossRef
29. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
    Simonetta M. Leto et al, 2015, Clin Cancer Res CrossRef
30. null
    Gayatri Gouda et al, 2020 CrossRef
31. MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors
    Valentina Angerilli et al, 2021, Biomedicines CrossRef
32. Clinicopathological profile and its association with peritoneal disease among gastric cancer patients
    Pavneet Kohli et al, 2021, Surgical Oncology CrossRef
33. Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells
    Maria Maddalena Laterza et al, 2021, Cancers CrossRef
34. Molecular Determinants of Gastrointestinal Cancers
    Francesca Battaglin et al, 2021, Advances in Oncology CrossRef
35. Resistance Mechanisms to HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma: A Systematic Review
    Dionne Blangé et al, 2022, Cancer Treatment Reviews CrossRef
36. Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapy
    Sergio González-Rubio et al, 2022, Nanoscale CrossRef
37. Long noncoding RNA NONHSAT160169.1 promotes resistance via hsa-let-7c-3p/SOX2 axis in gastric cancer
    Xuan Zhao et al, 2023, Sci Rep CrossRef
38. Deciphering drug resistance in gastric cancer: Potential mechanisms and future perspectives
    Jiahua Liu et al, 2024, Biomedicine & Pharmacotherapy CrossRef
39. HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments
    Magdalena K. Scheck et al, 2024, Cancers CrossRef